Everolimus Related Pneumonitis in MBC

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

NCT02444390 ·Status: COMPLETED ·Phase: NA

Eribulin in mTNBC Patients

NCT04541420 ·Status: COMPLETED

Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

NCT06561022 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

NCT03312738 ·Status: COMPLETED ·Phase: PHASE2

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

NCT05572645 ·Status: COMPLETED

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

NCT04395989 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

NCT03923179 ·Status: UNKNOWN ·Phase: PHASE2

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

NCT04917900 ·Status: UNKNOWN ·Phase: PHASE2

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

NCT05429294 ·Status: UNKNOWN ·Phase: PHASE2

Prediction of Everolimus-induced Interstitial Lung Disease

NCT01978171 ·Status: COMPLETED

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

NCT04900311 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

NCT03695341 ·Status: COMPLETED

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

NCT04418154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

NCT06341621 ·Status: RECRUITING ·Phase: PHASE3

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

NCT04033172 ·Status: UNKNOWN ·Phase: PHASE2

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344780 ·Status: ACTIVE_NOT_RECRUITING

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT06927180 ·Status: RECRUITING ·Phase: PHASE2

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

NCT02025712 ·Status: UNKNOWN ·Phase: PHASE2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

NCT05594095 ·Status: RECRUITING ·Phase: PHASE2

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

NCT05075512 ·Status: RECRUITING ·Phase: PHASE2

Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer

NCT07041437 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT03412383 ·Status: UNKNOWN ·Phase: PHASE2

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

NCT04334330 ·Status: UNKNOWN ·Phase: PHASE2

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

NCT05077449 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

NCT03772353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2